LDS/Medical Tests/Follicular Lymphoma, bcl-2/JH t(14;18), Real-time PCR, Bone Marrow

Follicular Lymphoma, bcl-2/JH t(14;18), Real-time PCR, Bone Marrow

Follicular Lymphoma is a slow growing Non-Hodgkin’s Lymphoma (NHL) commonly diagnosed in older adults (50 and older). Follicular lymphoma (FL) is a mature B-cell neoplasm composed of follicle center (germinal center) lymphocytes that typically has at least a partially follicular histologic pattern.

Follicular lymphoma predominantly involves lymph nodes, but may affect spleen and bone marrow. Peripheral blood may also be affected, as well as non-hematopoietic extranodal sites such as the gastrointestinal tract, skin, and other organs. The disease is often slow growing and can be present for many years before it is diagnosed; however, most patients have widespread disease at the time of diagnosis. Follicular lymphoma is characterized by the chromosome translocation t(14;18)(q32;q21). The t(14;18)(q32;q21) translocation is a translocation of the bcl-2 gene on chromosome 18 to the IgH locus on chromosome 14, leading to over-expression of bcl-2, a proto-oncogene. This over-expression blocks normal apoptosis, leading to overgrowth of follicle center cells leading to lymphoma genesis. The t(14;18) translocation is characteristic of B-cell lymphomas, occurring in up to 90% of follicular lymphomas. It is also found in 20% to 30% of diffuse large B-cell lymphomas, where it is an indicator of poor prognosis. The bcl-2/JH assay is useful for establishing diagnosis, predicting prognosis, monitoring therapeutic response, and detecting minimum residual disease (MRD) or recurrent disease. The detection of a translocation, t(14;18), involving the BCL-2 proto-oncogene, would support this diagnosis. BCL-2 has also been implicated in the pathogenesis of non-lymphoma cancers including breast cancer, endometrial cancer, malignant melanoma, prostate cancer, and lung cancer.

  • Diagnosis of follicular B-cell lymphoma harboring bcl-2, t(14;18)
  • Disease management and treatment monitoring
  • Estimate prognosis, and recurrence for patients with B Cell Lymphoma
  • Monitor minimal residual disease (MRD); and predict early relapse
  • Evaluation for possible use of anti-sense nucleic acid therapy
Positive results indicate that the cells carry the t(14;18) translocation and are reported as a ratio between the quantities of the amplified target gene bcl-2 and the control Ki-Ras gene. A positive result suports the diagnosis of a follicular B-cell lymphoma, a large diffuse B-cell lymphoma, or an undifferentiated B-cell lymphoma. If there is no bcl-2 (amplification ratio = 0), the result is reported as negative. Because translocation breakpoints sometimes occur outside the areas covered in this assay, a negative result does not rule out absence of this translocation. For monitoring MRD, we recommend monitoring changes with time (trend) rather than the absolute ratio from a single measurement.

Negative for t(14;18) translocation


 

Quantitative real-time polymerase chain reaction (PCR) assay. In addition to amplification of sequence specific gene for the mbr and the mcr region within the bcl-2 proto-oncogene on chromosome 18, and the immunoglobulin heavy chain region on chromosome 14 (JH), it amplifies the Ki-Ras gene which is used as an internal control that monitors DNA quality and is used for relative quantification. Results are reported as the ratio of amplified bcl-2 product to amplified internal control.

5 mL Bone Marrow in EDTA, Fresh tissue RPMI media.

Stability

  • Ambient:  1-3 days
  • Refrigerated: 3-5 days
Leukemia and Lymphoma immunophenotyping (Peripheral blood and bone marrow analysis by flow Cytometry), CCND1/IgH by flow Cytometry, t(14;18) Translocation by FISH, Chromosome Analysis.
5-7 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login